Eric Dobmeier - 23 Jun 2025 Form 4 Insider Report for Structure Therapeutics Inc. (GPCR)

Reporting relationship: Director
Issuer ticker: GPCR
Reported as of: 23 Jun 2025
Net transaction value: $0
SEC form: 4
Accepted by SEC: 25 Jun 2025, 17:45:09 UTC
Prior SEC filing: 13 Jun 2025
Next SEC filing: 11 Jun 2026
Source filing: View source filing
Reporting owner signature: /s/ Jun Yoon, Attorney-in-Fact

Key filing fact

Eric Dobmeier filed Form 4 for Structure Therapeutics Inc. (GPCR) on 25 Jun 2025.

Key facts

This page summarizes Eric Dobmeier's Form 4 filing for Structure Therapeutics Inc. (GPCR).
1 reported transaction and 1 derivative row are listed below.
Accepted by SEC: 25 Jun 2025, 17:45.

Change

Previous filing in this sequence was filed on 13 Jun 2025.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001202785 Primary reporting owner

DOBMEIER ERIC

Relationship: Director
Address: C/O STRUCTURE THERAPEUTICS INC., 601 GATEWAY BLVD., SUITE 900, SOUTH SAN FRANCISCO
Signature: /s/ Jun Yoon, Attorney-in-Fact
Signature date: 25 Jun 2025

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

GPCR transaction Derivative

Share Option (right to buy)

Award

Transaction value: $0
Shares: +51,804
Change %
Price: $0.000000
Shares after: 51,804
Date: 23 Jun 2025
Ownership: Direct
Underlying class: Ordinary Shares
Underlying amount: 51,804
Exercise price: $7.37
Footnotes: F1, F2, F3

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 3 footnotes

Footnote F1

The option exercise price per share is equal to the fair market value per Ordinary Share on the grant date based on the trading price of the Issuer's American Depositary Shares ("ADSs").

Footnote F2

The shares vest in equal monthly installments over the 12 months following June 23, 2025, provided that the grant will in any case be fully vested on the date immediately prior to the date of the Issuer's 2026 annual shareholder meeting,

Footnote F3

The Ordinary Shares of the Issuer may be represented by ADSs. Each ADS represents three Ordinary Shares of the Issuer.